Premium
Repeated treatment with chimeric anti‐CD4 antibody in multiple sclerosis
Author(s) -
Lindsey R. J. W.,
Hodgkinson S.,
Mehta R.,
Mitchell D.,
Enzmann D.,
Steinman L.
Publication year - 1994
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410360210
Subject(s) - multiple sclerosis , cd8 , immunology , monoclonal antibody , medicine , antibody , antigen , t lymphocyte , lymphocyte , monoclonal
We treated 21 multiple sclerosis patients with two to four doses of cM‐T412, a chimeric monoclonal antibody against the CD4 antigen found on helper/inducer T lymphocytes. The mean number (± standard error) of circulating CD4 lymphocytes decreased from 888 (± 81) cells/mm 3 at baseline to 246 (± 18) after treatment. At 1 year after the last treatment, the CD4 count had recovered to only 335 (± 32). The antibody had no effect on CD8 lymphocytes, B lymphocytes, or other leukocytes. Side effects were minimal. Despite the prolonged depletion of CD4 lymphocytes, no opportunistic infections occurred. Only 1 patient had a possible allergic reaction. Most patients were clinically stable, but a few progressed. We conclude that repeated treatment with cM‐T412 is effective in reducing the number of circulating CD4 lymphocytes and has no limiting side effects.